LeonaBio, Inc.
LONA
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.62M
Close$
Share Statistics
| Market cap | $26.62 Million |
|---|---|
| Enterprise Value | $-5,124,763.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-24.7 |
| Beta | 2.12 |
| Outstanding Shares | 4,275,762 |
Return
| Return on Equity | -421.06% |
|---|---|
| Return on Assets | -248.63% |
| Return on Invested Capital | -250.80% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | -0.1 |
| Price to Sales | - |
| Price to Book Ratio | 0.82 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.11 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-1.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Athira Pharma Inc
19 employees
CEO: Mark J. Litton LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of ne...